Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Using Circulating Tumor DNA to Target Immunotherapy
Clinical Breakthroughs

Using Circulating Tumor DNA to Target Immunotherapy

By Will DossAug 3, 2021
Share
Facebook Twitter Email
Maha Hussain, MBChB, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, was co-author of the clinical trial published in Nature.

Using circulating tumor DNA to identify patients at risk of urothelial cancer relapse after surgical resection could help improve post-surgery treatment, according to a study published in Nature.

Patients who test positive for circulating tumor DNA (ctDNA) after surgery and who were treated with immunotherapy had improved disease-free survival compared to patients who were positive for ctDNA but did not receive immunotherapy. These results demonstrate the power of personalized medicine in cancer therapy, according to Maha Hussain, MBChB, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology and a co-author of the study.

“Better risk prediction allows for better individualized therapy intensification targeting micro-metastatic disease in patients who are at risk of relapse,” said Hussain, who is also deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Determining whether or not a patient has remaining micrometastatic disease after surgery with or without prior pre-operative neoadjuvant chemotherapy has been historically difficult, according to the authors. Many patients who are actually cured by surgery, with or without neoadjuvant chemotherapy, receive additional systemic therapy based on post-surgery pathology. Other patients with residual microscopic disease presence may not receive potentially beneficial treatment until disease progression has become detectable by imaging.

“Clearly, in oncology one size does not fit all,” Hussain said.

The presence of ctDNA is considered likely evidence of systemic disease and is increasingly used as a biomarker for cancer relapse in patients who’ve undergone surgical resection. Testing for ctDNA offers advantages in identifying patients with residual systemic micrometastasis, according to Hussain.

In the current study, investigators sequenced urothelial tumor cells and identified 16 tumor-specific mutations. If a patient sample showed evidence of two or more of these mutations, that patient was considered ctDNA-positive.

Patients were enrolled in a randomized study comparing outcomes for patients after surgical resection for urothelial cancer. One group of patients received atezolizumab, a PD-L1 immunotherapy, while the other group was simply observed after surgery.

While atezolizumab did not show a significant improvement in overall survival among all patients, those patients who were ctDNA-positive post-surgery and received atazolizumab did show improvement compared to similar patients who were ctDNA-positive but did who not receive the treatment. In fact, 18 percent of patients who were ctDNA-positive and received atezolizumab had their ctDNA completely cleared, a measure that was associated with improved outcomes.

This detection and treatment method does have limitations, according to the authors. Using ctDNA to detect cancer relapse only detected 60 percent of relapsed cancers in the observation group, likely a result of low ctDNA after resection of the primary tumor. While there is room for improvement on detection using ctDNA, this personalized approach could be a framework for post-surgical cancer care, according to Hussain.

“Better technologies in the future could further help these patients,” Hussain said.

The study was sponsored by F. Hoffmann-La Roche Ltd/Genentech.

Cancer Genetics Research
Share. Facebook Twitter Email

Related Posts

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.